Latest news from ophthalmic research as to the developing of an effective and safe treatment for Acanthamoeba Keratitis.
At the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Baltimore 7-11 May 2017, ODAK Consortium, led by SIFI, presented two posters describing the latest pharmaceutical development of eye drops containing PHMB 0.08% to treat Acanthamoeba Keratitis. This is a rare disease which can cause blindness without proper treatment.
In the Poster “A 26-week repeated-dose toxicity study of PHMB 0.08% ophthalmic solution in rabbits” it has been assessed the eye drops safety in rabbit after a 26-week period of administration.
In the Poster “Ocular safety and tolerability of high dose PHMB (Polyhexanide) in healthy volunteers” excellent results have been reported about PHMB eye drops safety at three different concentrations (0.08%; 0.06%; 0.04%), which have been tested on 90 healthy volunteers enrolled in Phase I clinical trial.
The outcomes of both studies, presented at ARVO, provide a clear evidence to support the further development of PHMB 0.08% eye drops to Phase III clinical trial on patients suffering from Acanthamoeba Keratititis.
Links to posters (from www.oculistaitaliano.it)